NRx Pharmaceuticals, Inc.

NRXP · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$5,890-$17,580-$5,512-$9,078
Dep. & Amort.$41$0$0$1
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$67$12$0
Change in WC$567-$516$0$548
Other Non-Cash$2,391$14,001$2,020$7,065
Operating Cash Flow-$2,891-$4,028-$3,480-$1,464
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions-$2,561$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$2,561$0$0$0
Financing Activities
Debt Repay.-$225$378$4,680$3,320
Stock Issued$9,952$1,012$3,255-$2,059
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$1$0-$350$0
Financing Cash Flow$9,726$1,390$7,585$1,261
Forex Effect$0$0$0$0
Net Chg. in Cash$4,274-$2,638$4,105-$203
Supplemental Information
Beg. Cash$2,910$5,548$1,443$1,646
End Cash$7,184$2,910$5,548$1,443
Free Cash Flow-$2,891-$4,028-$3,480-$1,464
NRx Pharmaceuticals, Inc. (NRXP) Financial Statements & Key Stats | AlphaPilot